GoldBamboo.com - Knowledge is strong medicine
  

Systematic Management of High Cholesterol Utilizing Computer Monitoring - Article


  Not Signed In - Sign In / Register








Cholesterol

 



Clinical Trial: Systematic Management of High Cholesterol Utilizing Computer Monitoring

This study is not yet open for patient recruitment.
Verified by Department of Veterans Affairs August 2005

Sponsors and Collaborators: Department of Veterans Affairs
Research Foundation of the University of Pittsburgh Cardiovascular Institute
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00133094

Purpose

Employing a physician-directed case management system, utilizing a Certified Registered Nurse Practitioner (CRNP) in conjunction with computer-based decision support technology (CDST) will result in significantly lower total cholesterol and a lower low density lipoprotein cholesterol in a group of subjects enrolled in a general medical clinic compared to subjects managed by primary care providers in the usual care group.
Condition Intervention
Hypercholesterolemia
 Drug: Simvastin
 Procedure: omputer-based decision support technology

MedlinePlus related topics:  Cholesterol

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study

Official Title: Management of Hypercholesterolemia Utilizing a Case Management System, Incorporating Computer-Based Decision Support Technology

Further Study Details: 
Primary Outcomes: Total cholesterol and LDL-C cholesterol lowering
Secondary Outcomes: Verification that the decision support program provides equivalent recommendations for management of elevated cholesterol as would an expert in the management of hypercholesterolemia
Expected Total Enrollment:  220

Atherosclerosis affects 7 million patients and causes approximately 50% of all deaths in the United States. A reduction in modifiable risk factors (especially smoking, hypertension and hypercholesterolemia) is associated with a 30% reduction in acute coronary events. Clinically, fewer than 25% of patients achieve this degree of risk reduction because of significant barriers to implementation of effective risk reduction programs and wide variance in the management of hypercholesterolemia.

Recognition that a physician-directed case management system utilizing a certified registered nurse practitioner (CRNP) and computer-based decision support technology (CDST) offers the potential to implement disease management guidelines consistently and effectively is the impetus for this project. This project will demonstrate that enhanced compliance with the National Cholesterol Education Program (NCEP) guidelines can be achieved in a randomized trial conducted in subjects enrolled in a general medical clinic. The way in which hyperlipidemia will be managed is determined by randomization of the PCP providers to either the usual care group or to the intervention group, in which the management of subjects is delegated to the CRNP in conjunction with the CDST, under the supervision of the physician- investigators. Approximately 220 hypercholesterolemic subjects who are eligible for risk reduction according to NCEP guidelines will be recruited in equal numbers from subjects enrolled in the primary care clinic, beginning in 2005.

The physician-directed case management system employed in this project utilizes a management algorithm for lowering LDL-C cholesterol to the goal of less than 70 mg%. Stepwise increases in simvastatin dose to a maximum of 80 mg/day are used. Surveillance of symptoms and laboratory data to detect adverse side effects of the intervention precedes each increase in simvastatin dose. The CRNP will implement the management algorithm and concentrate on subject adherence, which is judged to be an important element in promoting compliance. The CRNP will initiate contact with the subject whenever a decision point is reached in the treatment algorithm, a deviation from the management algorithm occurs or an adverse reaction is detected. The case management model has been shown to be effective in achieving treatment goals in conditions such as hypercholesterolemia and diabetes mellitus.

This study will test hypothesis I, that employing a physician-directed case management system, utilizing a Certified Registered Nurse Practitioner (CRNP) in conjunction with computer-based decision support technology (CDST) will result in significantly lower total cholesterol and a lower low density lipoprotein cholesterol in a group of subjects enrolled in a general medical clinic compared to subjects managed by primary care providers in the usual care group.

A secondary aim of the project is to establish that computer-based decision support technology can be developed that will provide reliable clinical recommendations for the management of type II hyperlipidemia. This proposition will be tested by hypothesis II, that the computer-based decision technology provides advice for management of hyperlipidemia that is comparable to that of a cardiologist in the same institution.

Our physician-directed case-management system is expected to enhance guideline compliance by CDST monitoring of the subject’s compliance and cholesterol response to the management algorithm, thus contributing to improved outcomes for patients.

Eligibility

Ages Eligible for Study:  45 Years   -   70 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  1. Diagnosis of atherosclerosis and/or diabetes mellitus
  2. Males age 45-70
  3. Females age 55-70, at least 1 year post-menopausal
  4. No contraindication to HMG-Co A inhibitor therapy
  5. No administration of lipid lowering agents, except simvistatin less than or equal to 10 mg/day
  6. TSH level greater than 0.34 and less than 5.6 IU
  7. Urine protein less than or equal to 300 mg%
  8. Lipid profile consistent with Fredrickson type hyperlipidemia: total cholesterol greater than or equal to 140 mg% and less than or equal to 300 mg%; LDL-C greater than or equal to 100 mg%; and triglycerides less than 400 mg%
  9. Normal liver function tests (SGOT less than 42 IU; SGPT less than 60 IU and CPK less than 269 IU)
  10. One of the following diagnoses which establishes the presence atherosclerosis, making the subjects candidates for secondary prevention of complications or the presence of diabetes mellitus, which is considered an atherosclerotic equivalent according to the NECP III guidelines: uncomplicated acute myocardial infarction, more than 6 weeks previously; coronary arteriosclerosis (native artery and bypass grafts); prior aortocoronary bypass; prior PTCA; angina pectoris; peripheral vascular disease; or diabetes mellitus

Exclusion Criteria:

1) Women of childbearing age (2) Chronic liver disease and cirrhosis (3) Viral hepatitis, with residual hepatic dysfunction (4) Active alcohol abuse or dependence within the preceding 3 years (5) Drug abuse with or with out dependence within the preceding 3 years (6) Malignant neoplasms (7) Stroke (8) Dementia (9) Parkinson’s Disease (10) Multiple sclerosis (11) Triglycerides greater than or equal to 400 mg% (12) Other contra-indication to HMG-Co A administration such as cocomitant administration of drugs with known adverse interactions with simvastatin such as amiodarone, cimetidine, cyclosporin, tacrolimus, fibrates, HIV protease inhibitors, nefazodone, erythromycin, telithromycin clarithromycin, verpramil, itraconazole, ketoconozole, fluconazole danazol, or large quantities of grapefruit juice greater than 1 qt/day (13) Concurrent administration of lipid lowering agents or simvastatin at a dose greater than 10 mg/day at the time of entry into the protocol (14) Hypertension with systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 100 mm Hg with or without treatment (15) Any chronic illness in which the life expectancy is less than 3 years such as oxygen-dependent COPD

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00133094

Cathleen J Appelt, PhD MA BA      (412) 688-6000  Ext. 81.5016    cathleen.appelt@med.va.gov
Yvette Shipman, BA      (412) 688-6000  Ext. 815321    yvette.shipman@med.va.gov

Pennsylvania
      VA Pittsburgh Health Care System, Pittsburgh,  Pennsylvania,  15240,  United States
Mary B Walsh, RN  (412) 688-6000  Ext. 4897    mary.walsh3@med.va.gov 
Mark E Thompson, MD  (412) 688-6000  Ext. 815880    mark.thompson@med.va.gov 
Mark Ewing Thompson, MD,  Principal Investigator

Study chairs or principal investigators

Mark Ewing Thompson, MD,  Principal Investigator,  VA Pittsburgh Health Care System   

More Information

Study ID Numbers:  HFP 01-717; 00262
Last Updated:  August 19, 2005
Record first received:  August 18, 2005
ClinicalTrials.gov Identifier:  NCT00133094
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-08-23

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Cholesterol.

August 2, 2014



Page Updated: June 20, 2006
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use

Copyright © 2004-2014 - Anaconda Partners LLC - All rights reserved.